Opinion|Videos|August 12, 2024
Dr Parrondo shares Approach to Managing BTKi Treatment-Related Afib
An oncology specialist outlines their general approach to managing treatment-related atrial fibrillation in patients receiving BTK inhibitor therapy, incorporating insights from recent clinical data to inform their management strategies.
Advertisement
Episodes in this series
- Dr Parrondo:What is your general approach in managing treatment-related Afib in patients receiving treatment with BTKi inhibitors? What insights do recent data provide?
- Kaiser RWD -
Krackeler, et al. ASCO 2024. Abs 11158 @54:33 zanubrutinib go away over time. Less cardiac
- Kaiser RWD -
- What is the role of medications for anticoagulation and rhythm control? Dose reductions/holds?When do you involve cardiology?
- When may alternative therapy be warranted and what is your approach in these scenarios?
Advertisement
Related to this article
The top 5 OncLive TV videos of the week cover insights in bladder cancer, chronic myeloid leukemia, multiple myeloma, pancreatic cancer, and chronic lymphocytic leukemia.
Data for fixed-duration regimens in CLL suggest benefits over chemoimmunotherapy but still require improvements for high-risk patients.
Orelabrutinib produced efficacy improvements vs chemoimmunotherapy in previously untreated chronic lymphocytic leukemia.
Matthew S. Davids, MD, MMSc, discusses data from BRUIN CLL-322 that may shake up the CLL treatment paradigm.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Zidesamtinib in Pretreated ROS1+ NSCLC
2
Ivonescimab Plus Chemotherapy Sustains OS Benefit Across Western and Asian Patients in Pretreated EGFR-Mutated NSCLC
3
Sacituzumab Govitecan Yields Responses in Platinum-Resistant Ovarian Cancer
4
How Are Treatment Intensification and Sequencing Reshaping Care in Prostate Cancer and RCC
5